Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study
NCT06680427
Recruiting
The Siegel™ Transcatheter Aortic Valve (TAVR) early feasibility study objective is to assess the acute and long-term safety and feasibility of the Siegel TAVR device in adult subjects with symptomatic, severe native aortic stenosis eligible for the transcatheter aortic valve replacement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/10/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California +7 locations
Conditions: Aortic Stenosis Symptomatic
Register for Updates
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
07/10/2025
Locations: Banner Alzheimer's Institute ( Site 0110), Phoenix, Arizona +65 locations
Conditions: Alzheimer Disease, Dementia
Register for Updates
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
NCT05897424
Recruiting
Phase 2 open label extension study to evaluate SAR447537 (INBRX-101) in adults with AATD emphysema
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/10/2025
Locations: University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama +40 locations
Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Register for Updates
Stress and Resilience
NCT06457841
Recruiting
Alcohol and cannabis are the most misused psychoactive substances in the United States. The proposed research examines how personally relevant stressful experiences may lead to alcohol and cannabis use. The proposed research is also designed to identify possible targets for prevention and treatment efforts to help reduce drug use.
Gender:
ALL
Ages:
Between 18 years and 30 years
Trial Updated:
07/10/2025
Locations: Southern Methodist University, Dallas, Texas +1 locations
Conditions: Alcohol Use, Cannabis Use
Register for Updates
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187
Recruiting
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +23 locations
Conditions: Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
Register for Updates
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
NCT03486873
Recruiting
The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study. This study will consist of three phases: 1) First Course Phase, 2) Survival Follow-up Phase or 3) Second Course Phase. Each participant will transition to this extension study in one of the following three phases, depending on the study phase they were in at the completion of the par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Arizona Cancer Center at UMC North ( Site 0018), Tucson, Arizona +659 locations
Conditions: Solid Tumors, Hematologic Malignancies
Register for Updates
Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures
NCT03568292
Recruiting
This trial studies how well virtual reality (VR) works in reducing pain and anxiety in cancer participants undergoing bone marrow biopsy or lumbar puncture. Virtual reality may impact pain and anxiety during and after the procedure.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/10/2025
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Malignant Neoplasm
Register for Updates
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
NCT05609968
Recruiting
The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Infirmary Cancer Care ( Site 0418), Mobile, Alabama +176 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801
Recruiting
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immunotherapy with monoclonal antibodies, such as tiragolumab and atezolizumab, may help the body's immune... Read More
Gender:
ALL
Ages:
12 months and above
Trial Updated:
07/10/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +39 locations
Conditions: Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Rhabdoid Tumor, Rhabdoid Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Register for Updates
A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
NCT06687980
Recruiting
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Center for Dermatology Clinical Research- Site Number : 8400226, Fremont, California +51 locations
Conditions: Lichen Simplex Chronicus
Register for Updates
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005
Recruiting
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study: Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: City of Hope, Duarte, California +40 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Expanded Population Health Model Evaluation
NCT06044831
Recruiting
This study will evaluate the impact of a comprehensive wellness and social determinants of health intervention on cardiovascular health in a community setting of the Bonton neighborhood. Participants will not be assigned to intervention activities, but health and wellbeing indicators will be collected in relation to how they choose to participate in activities over the year.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2025
Locations: Baylor Scott & White Health and Wellness Center, Dallas, Texas
Conditions: Chronic Disease, Quality of Life
Register for Updates